AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05100537 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction
Description: The intervention has its roots in meditations and yoga practices. However, it is independent of religious purpose or affiliation.The weekly sessions include a range of mental and bodily practices, including awareness of emotions, awareness of thoughts, awareness of sensations. It involves full awareness of daily activities, using the breath as an anchor for attention.In addition to mindfulness practices and experiential work, psychoeducation and participants' sharing will clarify the issues of stress, stress management and how mindfulness is applied in daily situations and interpersonal communication.
Study NCT05100537 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: continuing a routine life
Description: No intervention will be made in the control group.
Study NCT04653493 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CAR engineered autologous T-cells
Description: Given IV~Following preconditioning with lymphodepleting chemotherapy (cyclophosphamide and fludarabine) patients will be treated with CD19 Chimeric Antigen Receptor (CAR) T cells as a single or split dose (day 0, 1 and 2, CAR cells will be intravenously infused at the 10%, 30% and 60% ratio respectively). Dosing of CD19 CAR-T cells will follow a dose-escalation schema, with dose changes based on dose-limiting toxicities.
Study NCT04653493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT04653493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT04653493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Given IV
Study NCT06177366 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Blood samples will be collected at diagnosis, in the same time as BOM is performed
Study NCT04856137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab Paclitaxel Ruxolitinib
Description: Rituximab 375mg/m2 on D1 of each cycle Paclitaxel 200mg/m2 on D1 of each cycle Ruxolitinib continuously given (D1-21)
Study NCT06213662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A for injection
Description: Botulinum toxin was injected into the upper esophageal sphincter of each patient
Study NCT05157126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin
Description: Liquid gentamicin administered at the open fracture site
Study NCT05157126 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal Saline
Description: Normal saline administered at the open fracture site
Study NCT05359393 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: a combination therapy including tislelizumab
Description: Patients will receive tislelizumab in combination with neoadjuvant radiotherapy and chemotherapy, and will be evaluated 2-3 weeks after completion of the treatment. Those patients who achieve complete clinical regression of the lesion can choose observation, but for those without CCR, surgical resection (TME of the primary lesion, surgical resection of metastases or other destructive local treatment) will be applied. Patients will continue to receive tislelizumab for one year after surgery or during observation.~For liver/pulmonary metastasis, the treatment plan is to implement large fraction radiotherapy for 4-8 times. For primary rectum lesion, short-course radiotherapy regimen through intensity-modulated radiotherapy will be applied with dose of 25Gy/5Fx.~Immunotherapy contains anti-PD-1 monoclonal antibody, Tislelizumab(200mg, d1, q3w x6, i.v). Chemotherapy adopts CAPEOX plan, including Capecitabine(1000mg/m2 bid, d1-14, p.o) and oxaliplatin(130mg/m2, d1, i.v).
Study NCT05996510 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound
Description: Shoulder ultrasound is performed using a linear ultrasound probe. The area under the suprascapular notch and the superior transverse scapular ligament is measured using the cross-sectional area measurement method.
Study NCT04550377 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: non-active medication
Study NCT06077526 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: P.E.A.K. Rx
Description: Pain Education + Physical Activity Group Based Intervention
Study NCT06077526 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will receive the community hospital's usual care.
Study NCT05729061 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Assist-Knee
Description: Investigational prosthetic knee-ankle device
Study NCT05729061 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Prosthetic Knee
Description: Commercially available prosthetic knee devices
Study NCT05729061 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Prosthetic Ankle
Description: Commercially available prosthetic ankle devices
Study NCT05729061 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Prosthetic Foot
Description: Commercially available prosthetic foot devices
Study NCT05938738 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEP-buddy
Description: PEP-buddy
Study NCT05729061 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ankle-Foot Orthosis
Description: Commercially available ankle-foot orthosis devices
Study NCT05605301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral 2-Deoxy-D-Glucose (2DG)
Description: 2DG will be formulated as an solid dosage form and administered orally.
Study NCT04977245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: Eight MBSR sessions of 1.5 hours per week
Study NCT04977245 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-Guided Mindfulness eCourse
Description: Six weeks of a mindfulness ecourse, and two weeks of coping skills training led by a licensed neuropsychologist
Study NCT05095532 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone marrow-derived mesenchymal stem cells
Description: MSC transplantation
Study NCT05095532 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard of Care
Study NCT05205473 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sciatic nerve block under ultrasound control with a electrostimulator peripheral nerves 12.5 ml 1% lidocaine
Description: Following the ultrasound visualization of the femoral nerve, a insulated injection needle was connected to the nerve stimulator . Under ultrasound visualization guidance, the needle of the electronic nerve stimulator was positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve, and a positive muscular response . Subsequently, the introduction of LA solution was initiated (12.5 ml 1% lidocaine).If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed.
Study NCT05205473 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sciatic nerve blockade under ultrasound control without a peripheral nerve stimulator 12.5 ml 1% lidocaine
Description: Under ultrasound visualization guidance, the needle owas positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve. Subsequently, the introduction of LA solution was initiated. The position of the needle was corrected 1-2 times according to the type of anesthetic spread. If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA (12.5 ml 1% lidocaine) along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed.
Study NCT05599776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smart ring assisted physiotherapeutic intervention
Description: the effect of a smart ring (Oura), a wearable activity tracker assisted physiotherapeutic intervention on the risk of poor outcome measured on patient reported post-operative outcome (Oxford Knee Score) 12 months after a primary total knee replacement.
Study NCT04760002 — intervention group
Intervention type: DEVICE
Intervention: NightOwl
Description: The NightOwl consists of a small sensor device which is placed on the fingertip and a smartphone app that is connected to an encrypted cloud-based analytics platform within the European Union, the NightOwl software. It is self-applied by attaching the sensor to the fingertip by means of an adhesive patch. The NightOwl sensor acquires accelerometer data and reflectancebased photoplethysmography (PPG) from which it derives actigraphy (sleep/wake behavior), SpO2, peripheral artery tone (PAT) and pulse rate, among other features. A PAT analysis derives changes in caliber of arteries elicited by alterations in the contractile activity of vascular smooth muscle and are referred to as changes in arterial tone. The end state of the apnea-hypopnea events are associated with sympathetic activation.
Study NCT05129033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone tablet
Description: Basic medication for allergic airway inflammation such as asthma and ABPA, to relieve inflammation. Reduction may failed if disease exacerbate.
Study NCT05129033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: itraconazole
Description: Anti-fungal medication to reduce fugal load.
Study NCT05129033 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Anti-IgE monoclonal antibody, used for high IgE allergic disease.
Study NCT05621525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBP-398
Description: BBP-398 (formerly known as IACS-15509) is a potent, selective, orally active allosteric inhibitor of SHP2, a tyrosine phosphatase that plays a key role in the RTK -MAPK signal transduction pathway. Key components of the MAPK pathway include the small GTPase RAS, the serine/threonine-protein kinase RAF, mitogen-activated protein kinase (MEK) and ERK. In cells, SHP2 binds to phosphorylated tyrosine residues in the intracellular domain of RTKs such as the EGFR, leading to activation of the downstream MAPK signaling pathway.
Study NCT06023836 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ESWT
Description: Patients in this group received three sessions of ESWT (MASTERPLUS MP 200 ENERGY 2 trademarked ESWT device) at an energy density of 2 bars and a frequency of 2,000 shocks/min at 12 Hz for three weeks, each session once a week. Each of the five most sensitive and painful points was given 400 pulses in the supine position
Study NCT06023836 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: Dry needling with Seirin branded 0.6\*50 mm acupuncture needles will be performed for 3 sessions with one week intervals for the trigger point detected by manual palpation in the medial gastrocnemius, lateral gastrocnemius, soleus, flexor digitorum brevis, quadratus plantae, abductor hallucis brevis muscles of the patients in the group.
Study NCT06100783 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Depot-medroxy Progesterone Acetate Injectable Contraceptives
Description: Depot-medroxy progesterone acetate injectable contraceptives
Study NCT04753892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3SM2-G-CRM197 with squalene adjuvant
Description: Immune challenge agent
Study NCT04421326 — intervention group
Intervention type: OTHER
Intervention: Analysis of the clot
Description: Blood sampling at the site of intracranial occlusion during Mechanical Thrombectomy
Study NCT06347042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: qigong exercise + routine medical treatment +Anti-inflammatory diet
Description: 1. Qigong exercise is from traditional Chinese medicine exercise . Qigong is system coordinating slow-flowing movement, deep rhythmic breathing, and a calm meditative state of min Frequency of exercise 3 days a week and 60 min a day, including a 15 min warm up, 40 min and 5min cool down.
Study NCT06347042 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: routine medical treatment +Anti-inflammatory diet only
Description: 1. Anti-inflammatory diet is characterized by the exclusion of potential inflammatory foods, such as gluten, dairy, free sugar, and ultra-processed food, rich in sugar, hydrogenated fat, and food additives. are some foods with recognized anti-inflammatory potential~2. routine medical treatment
Study NCT06347042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: routine medical treatment +Anti-inflammatory diet only
Description: 1. Anti-inflammatory diet is characterized by the exclusion of potential inflammatory foods, such as gluten, dairy, free sugar, and ultra-processed food, rich in sugar, hydrogenated fat, and food additives. are some foods with recognized anti-inflammatory potential~2. routine medical treatment
Study NCT05637060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Test Drug
Description: One single dose of Vaptor 20 mg will be administered to subjects after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time.
Study NCT05637060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Drug
Description: One single dose of Vaptor 20 mg will be administered to subjects after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time.
Study NCT05210062 — intervention group
Intervention type: OTHER
Intervention: Iterative exposure to suxamethonium during ECT sessions
Description: The study is divided into 2 phases: phase P and phase E. Phase P: 10 patients to be included in 1 month with a unique dose of suxamethonium during one session of ECT. One blood sample will be taken from patients before their index ECT session. The objective is to evaluate the feasibility of antibody detection relative to the main objective of the study, to ensure the number of patients to include in phase E (analysis in the following month). Depending on the frequency of antibodies detected, particularly IgG4, the number of patients required for phase E will be revised. If no antibodies are detected, the study will be discontinued.~Phase E: 60 patients to be included in 12 months with 5 blood samples: before the first session of ECT (S0), at 2 weeks (S2), at 4 weeks (S4), between 6 - 14 weeks (preferably at S10) and at 6 months (M6). Only first-time patients or those not having been exposed to ECT in the past 10 years will be included in this phase.
Study NCT05637060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference Drug
Description: One single dose of Crestor 20 mg will be administered to subjects after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time.
Study NCT05637060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Drug
Description: One single dose of Crestor 20 mg will be administered to subjects after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time.
Study NCT05740774 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 3D ultrasound
Description: 3D ultrasound scanning of the resected tongue tumor will be performed. The margin analysis will be made using the 3D ultrasound image.
Study NCT06384092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Sun Protection Cream
Description: Apply directly on the designated site till absorbed.
Study NCT05977738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin calcium
Description: Daily Pitavastatin administration
Study NCT06384092 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Benchmark Sun Protection Cream
Description: Apply directly on the designated site till absorbed.
Study NCT05959889 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo tablets for 4 cycles of AC.
Study NCT05959889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Patients will receive motelukast 10 mg for 4 cycles of AC.
Study NCT05615025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Anesthesia will be maintained by sevoflurane.
Study NCT05615025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Anesthesia will be maintained by propofol.
Study NCT05350956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPO-RA (Herombopag)
Description: During the correction period, subjects will receive a dose of Herombopag starting at 5-7.5mg once daily, orally for 14 days, subject to dosing adjustment (or discontinuation) depending on their platelet response or at the investigator's discretion. In the secondary prophylaxis phase, Herombopag 5mg once daily, starting 5 days before antineoplastic therapy and continuing for 10-14 days.
Study NCT05350956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPO-RA (Herombopag) and rhTPO(Recombinant human thrombopoietin)
Description: During the correction period, subjects will receive a combination of Herombopag and rhTPO, Herombopag starting at a recommended dose of 5mg once daily for 14 days. The recombinant human thrombopoietin dose is 300U/kg. bw/day or 15000U/day per person, once daily, for 14 consecutive days (or as determined by the investigator). In the secondary prophylaxis phase, Herombopag 5mg once daily, starting 5 days before antineoplastic therapy and continuing for 10-14 days.
Study NCT06674863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive a low literacy educational supplement
Study NCT06674863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Undergo a structured interview
Study NCT06674863 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Undergo a structured interview
Study NCT06674863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06674863 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06674863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Receive standard SCP
Study NCT06674863 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Care
Description: Receive standard SCP
Study NCT06674863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Receive a tailored SCP
Study NCT04515810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Use smartphone application
Study NCT04515810 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Engage in standard care
Study NCT04515810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04515810 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05090033 — intervention group
Intervention type: OTHER
Intervention: ofatumumab
Description: There is no treatment allocation. Patients administered ofatumumab by prescription that have started before inclusion of the patient into the study will be enrolled.
Study NCT05979779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HU6
Description: HU6 is being evaluated for its efficacy in improving liver fat content in subjects with Nonalcoholic Steatohepatitis (NASH)
Study NCT05979779 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06081244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: 10 mg/kg twice on Days 1 and 8 of a continuous 21-day treatment cycle
Study NCT06081244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg every 3 weeks (q3w)
Study NCT05723588 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active repetitive transcranial magnetic stimulation
Description: Active rTMS is a non-invasive brain stimulation intervention that is FDA cleared as a treatment for smoking cessation in adults.
Study NCT05723588 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham repetitive transcranial magnetic stimulation
Description: Sham rTMS involves no brain stimulation, but appears to the participant and provider to be active rTMS.
Study NCT05723588 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy for smoking cessation
Description: All participants will receive five sessions of cognitive behavioral therapy (CBT) for smoking cessation.
Study NCT05723588 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: cognitive behavioral therapy for smoking cessation
Description: All participants will receive five sessions of cognitive behavioral therapy (CBT) for smoking cessation.
Study NCT05723588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine replacement therapy
Description: All participants will receive nicotine replacement therapy in for the form of 21 mg, 14 mg, and/or 7 mg nicotine patches (based on smoking quantity) and a rescue method such as nicotine lozenge or nicotine gum.